http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
-
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
-
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
-
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
-
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
-
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
-
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
-
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
-
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
-
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
-
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
-
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
-
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video
-
Amylyx Pharmaceuticals (AMLX) Confirms FDA Approval of RELYVRIO for the Treatment of ALS
-
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
-
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
-
Amylyx Pharmaceuticals (AMLX) Reports Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035
-
Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds
-
Amylyx Pharmaceuticals (AMLX) Announces FDA Ad Comm Backing of ALS Drug AMX0035
-
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
-
Amylyx Pharmaceuticals (AMLX) Confirms Stock Trading Halted Today Ahead of FDA Meeting
-
Amylyx Pharmaceuticals Stock Trading Halted Today
-
Amylyx Pharmaceuticals (AMLX) Posts Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035
-
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035
-
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
-
Amylyx Pharmaceuticals (AMLX) Announces FDA AdCom to Reconvene to Review AMX0035 on September 7, 2022
-
Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022
-
Amylyx Pharmaceuticals (AMLX) Launches ALBRIOZA in Canada for Treatment of ALS
-
Amylyx Pharmaceuticals Announces ALBRIOZA™ is Now Available in Canada for the Treatment of ALS
-
Amylyx Pharmaceuticals (AMLX) Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
-
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
-
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
-
Amylyx Pharmaceuticals (AMLX) Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7
-
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
-
Amylyx Pharmaceuticals (AMLX) Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
-
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
-
Amylyx Pharmaceuticals (AMLX) Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
-
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
-
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
-
Amylyx Pharmaceuticals (AMLX) Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
-
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
-
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
-
Amylyx Pharma (AMLX) Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
-
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
-
Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting
-
Amylyx Pharmaceuticals (AMLX) Confirms Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS
-
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
-
Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS
-
Amylyx Pharmaceuticals Stock Trading Halted Today
